Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases
Markets2017-03-14
19 Views
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
Source: Pharmaceutical Daily
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
